SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-23-001783
Filing Date
2023-03-21
Accepted
2023-03-21 08:00:25
Documents
14
Period of Report
2023-03-21
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_032123.htm   iXBRL 8-K 14596
2 PRESS RELEASE exh_991.htm EX-99.1 55691
  Complete submission text file 0001171843-23-001783.txt   277521

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3069
4 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25640
5 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 34011
6 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 22139
8 EXTRACTED XBRL INSTANCE DOCUMENT f8k_032123_htm.xml XML 3126
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40908 | Film No.: 23747871
SIC: 2836 Biological Products, (No Diagnostic Substances)